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The treatment of cancer in children has several side 
effects, including ototoxicity. Inner ear structures may be 
affected and hearing loss may ensue. Aim: To estimate the 
prevalence of hearing loss in patients with cancer using the 
American Speech-Language-Hearing Association (ASHA), the 
Pediatric Oncology Group Toxicity (POGT), and the Bilateral 
Hearing Loss (PAB) criteria. Study design: a prospective study. 
Material and Methods: 94 patients admitted between 2003 
and 2004 were analyzed. Visual inspection of the external 
auditory meatus and an audiologic evaluation were done. 
Descriptive statistics was used to characterize the sample, 
and Kappa statistics was used to investigate concordance of 
hearing loss in the three types of classification. Results: The 
prevalence of hearing loss was 42.5% using ASHA, 40.4% using 
POGT, and 12.8% using PAB. The concordance of hearing 
loss was weak for POGT and PAB (k=0.36) and for PAB and 
ASHA (k=0.33). The concordance between ASHA and POGT 
was almost perfect (k=0.96). Conclusions: Hearing loss is an 
important side effect of the treatment of cancer in children. 
Periodic audiology monitoring is recommended to detect 
early hearing loss and to revise the treatment if necessary. 
Adoption of a classification system that detects mild hearing 
loss (ASHA) is recommended.
Keywords: childhood cancer, ototoxicity, hearing loss, 
chemotherapy.
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INTRODUCTION
The increase in survival rates of children and ado-
lescents with malignant tumors in the last two decades 
reflects more effective treatments - including combined 
chemotherapy, better diagnostics, better surgical techni-
ques and radiotherapy, the combined use of different tre-
atment modalities, better support and increase in survival 
and quality of life1-3. Nonetheless, children and teenagers 
with cancer are exposed to the most diverse sort of side 
effects, especially when submitted to chemotherapy, 
which despite being one of the most promising means to 
fight cancer, depending on the chemotherapeutic agents 
employed it can cause undesirable side effects.
Side effects may manifest themselves earlier on, or 
in the long run, depending on treatment type and child’s 
age. Hearing loss is among these many side effects4,5.
Ototoxicity is defined as a toxic reaction that affects 
the inner ear, both the auditory and/or the vestibular sys-
tem and may cause hearing loss6. Ototoxicity has taken 
an important role, especially in younger children, having 
seen that it is usually irreversible and, thus, it means a 
loss in the long run7,8.
One commonly used classification to assess hearing 
losses in audiology clinics is the one from Davis and Silver-
man (1970), mentioned by Russo and Santos (1993)9. It is 
based on determining the degree of hearing loss from air 
conduction threshold average in the frequencies of 500, 
1000 and 2000 Hz - the ones most important for speech, 
considering normal hearing until 25 dBHL (decibel hearing 
level). However, this classification is the same for adults 
and children, regardless of the disease, and today we also 
consider the frequency of 4,000 Hz as being important.
According to Haggard and Primus (1999)10, the 
scales used to classify hearing loss are not similar, and 
such fact makes it difficult to compare prevalence. There 
is much disagreement on which would be the most ade-
quate classification to use for hearing loss, however the 
consensus is that it is important to adopt a differentiated 
hearing loss classification for children. According to Nor-
thern and Downs (1989)11, the ideal tonal threshold for a 
child is 15 dB or less in all audiogram frequencies (from 
250 to 8000 Hz), differently from adults, in which the mean 
value between 20-25 dB is acceptable.
In assessing the child’s hearing loss, it is important 
to highlight that even mild loss, which would not impact 
adults, may interfere in children’s capacity to acquire and 
develop language skills. Hearing loss, even if transitional, 
between 25 and 35 dBHL, this reduction is not enough to 
prevent the child from hearing, however, it may impair 
the child’s ability to understand some phonema11.
In 1991, the American Speech-Language-Hearing 
Association - ASHA (Hersh and Johnson, 2003)12 proposed 
a hearing loss classification for children. Hearing loss is 
determined according to the different degrees of difficulty 
for communication, considering normal hearing the one 
between 10 and 15 dBHL, mild hearing loss between 
16 and 25 dBHL, light hearing loss between 26 and 40 
dBHL, moderate hearing loss between 41 and 55 dBHL, 
moderately severe hearing loss between 56 and 70 dBHL, 
severe hearing loss between 71 and 90 dBHL and profound 
hearing loss those above 90 dBHL.
In 1994, the American Speech-Language-Hearing 
Association - ASHA proposed another specific classification 
for patients treated with ototoxic drugs, the Ototoxicity 
Criteria (ASHA, 1994)13. Such classification classifies hea-
ring loss by means of comparing the results of previous 
audiologic evaluations, in A (threshold increase in 20 dB 
or more in one frequency), B (threshold increase in 10 dB 
or more in two sequential frequencies) and C (no response 
in three sequential frequencies, which were present in 
prior audiologic evaluations).
According to Brock et al. (1991)8, hearing loss 
specifically induced by cisplatin has been measured by 
pre and post treatment audiograms. Notwithstanding, the 
existing classifications for hearing loss are not adequate to 
be used in children with cancer, since the most common 
classifications usually determine the degree of hearing 
loss based on the mean value of air conduction in the 
frequencies of 500, 1000 and 2000 Hz (as the classifica-
tion from Davis and Silverman, 1970). Thus, the authors 
proposed an exclusive classification for children treated 
with cisplatin or other ototoxic drugs. In such classifica-
tion, hearing loss is classified in levels, according to the 
frequency that presented tonal threshold below 40 dBHL: 
Level 0 (hearing thresholds below 40 dBHL in all the 
frequencies), Level 1 (hearing loss above or equal to 40 
dBHL in 8000 Hz), Level 2 (Hearing loss above or equal 
to 40 dBHL in 4000 Hz and below), Level 3 (hearing loss 
above or equal to 40 dBHL in 2000 Hz and below) and 
Level 4 (hearing loss above or equal to 40 dBHL in 1000 
Hz and in lower frequencies). The classification proposed 
considers that hearing loss above or equal to 40 dBHL, in 
any frequency, implies loss in speech recognition and, the 
more it affects speech frequencies, the more harm it brings. 
The authors consider that after 40 dBHL the hearing loss 
was surely caused by an external agent, the ototoxic drug 
in this case - and that in lower intensities, the hearing loss 
could happen due to other agents.
In 1999, the Pediatric Oncology Group Toxicity 
- POGT (Huang et al., 2002)14 developed a hearing loss 
classification for children treated with chemotherapeutic 
agents. This classification also classifies the loss in levels: 
Level 0 (normal hearing), Level 1 (hearing loss between 
20 and 40 dBHL in frequencies above 4000 Hz), Level 2 
(hearing loss above or equal to 40 dBHL in frequencies 
above or equal to 4000 Hz), Level 3 (hearing loss above 
or equal to 40 dBHL in frequencies above 2000 Hz) and 
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Level 4 (hearing loss above or equal to 40 dBHL in 2000 
Hz and below). This classification considers the hearing 
loss above or equal to 20 dBHL in the frequencies above 
4000 Hz already implies in speech recognition loss and 
that, the more it affects frequencies between 2000 Hz and 
below, the greater is the communication difficulty.
Another classification was proposed by the National 
Cancer Institute (NCI), the Common Toxicity Criteria ver-
sion 2.0 (CTC) (1999)15. This classification classifies hearing 
loss in levels from 0 to 4, according to the symptoms and 
the results from the audiologic evaluation: Level 0 (nor-
mal hearing), Level 1 (mild hearing loss, no complaints), 
Level 2 (tinnitus or hearing loss that does not require the 
use of a hearing aid), Level 3 (tinnitus or hearing loss 
that requires the use of a hearing aid), Level 4 (severe 
unilateral or bilateral hearing loss). This classification is 
subjective - it is based on clinical complaints and on the 
judgment regarding the relevance or not of using a hea-
ring aid - issues which are difficult to assess, especially 
in small children.
Recently, another classification was proposed by 
the National Cancer Institute (NCI), the Common Termi-
nology Criteria for Adverse Events version 3.0 (CTCAEv3) 
(2003)16. This classification breaks down hearing loss in 
levels from 1 to 4, by comparing the results of prior au-
diologic assessments: Level 1 (threshold increase between 
15 and 25 dB in relation to the initial audiologic exam, in 
two or more sequential frequencies in at least one ear), 
Level 2 (threshold increase between 25 and 90 dB in two 
sequential frequencies), Level 3 (threshold loss greater 
than or equal to 20 dB bilaterally in speech frequencies, 
or greater than or equal to 30 dB unilaterally) and Level 
4 (hearing loss requiring a hearing aid or even a cochlear 
implant).
Although the classifications proposed by Brock et 
al. (1991)8 and by the Pediatric Oncology Group Toxicity 
(POGT)14 were made in order to assess ototoxicity in 
specific situations, all of them used the same auditory 
thresholds in accordance with intensity in different fre-
quencies, which can be used independently from the 
assessment carried out prior to treatment. In the literature 
we did not find any study that compared and discussed the 
relevance of using these classifications. Having said that, 
the goals of the present investigations are to determine 
hearing loss prevalence among children and teenagers 
with cancer using the classifications from the American 
Speech-Language-Hearing Association (ASHA), of Bilate-
ral Hearing Loss (BHL) and from the Pediatric Oncology 
Group Toxicity (POGT), and check the agreement of these 
three classifications in the diagnosis of hearing loss.
MATERIALS AND METHODS
The present investigation was developed in an 
institute which is the national reference center for the 
treatment of pediatric cancer, and was approved by the 
Research Ethics Committee of the School of Public Health 
of the University of São Paulo, under protocol # 1186 and 
the Ethics Committee for the Analysis of Research Projects 
- CAPPesq of the University of São Paulo Hospital Execu-
tive Board, protocol # 104/06.
After surveying patients’ charts, we noticed that 325 
new cases were seen in 2003; and 342 in 2004; most of 
them, 469 children (= 70.3%), did not have the diagnosis 
of cancer confirmed and were referred to another unit for 
specific treatment.
Therefore, we selected 87 new cases seen in 2003 
and 111 new cases seen in 2004 for our investigation, 
making up a total of 198 patients. Of these, 44 (22.2%) 
died and 12 (6.1%) were transferred to other treatment 
centers located in other cities/capitals, leaving a total of 
142 patients. Since pre-treatment audiologic evaluation is 
not carried out routinely in this institute, these patients 
were not included in this study.
We first assessed the medical chart of these patients 
in order to fill out the form and, later we scheduled their 
audiologic exam.
Among the 142 patients, we were able to do the 
audiologic exam in 94 patients.
 
The audiologic exam
We first carried out an anamnesis in order to look 
for any symptom or hearing loss complaint. Later on, we 
visually inspected the external acoustic meatus with an 
otoscope, checking for wax or any other thing that could 
prevent these exams. If a wax ball was seen, the patient 
was then referred to the otorhinolaryngologist to remove 
it, and only afterwards the exam was carried out. 
Following that, auditory thresholds were evaluated, 
by means of conditioned response methods (audiometry 
with visual reinforcement - children of up to two years of 
age; conditioned audiometry within a ludic activity - chil-
dren between 2 and 5 years; or tonal threshold audiometry 
- children above 5 years, with the aim of determining their 
hearing thresholds. This test was carried out in an acoustic 
booth, using the Maico MA-41 audiometer with TDH-39 
phones, duly calibrated according to current standards, in 
the frequencies of 250 to 8000 Hz and, by bone conduction, 
in the frequencies of 500 to 4000 Hz, whenever necessary 
in order to confirm the findings. Later on, we carried out 
tympanometry and acoustic reflexes test using the Danplex 
ZA-28 impedance meter device. All the tests were carried 
out by the same audiologist (AMS).
In order to define the hearing loss, three classifi-
cations were used: American Speech-Language-Hearing 
Association (ASHA), Bilateral Hearing Loss (BHL) and the 
Pediatric Oncology Group Toxicity (POGT).
The sample was characterized by means of descrip-
tive statistics (mean, standard deviation, median and pro-
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portions) and we analyzed the three classifications insofar 
as their agreement is concerned in terms of hearing loss 
by means of the Kappa statistics. In all statistical analysis 
we used the 5% level of statistical significance.
We used the Epi Info v. 6.04 for DOS software for 
database double entry and data consistence; and the SPSS 
v. 12.0 for Windows for statistical analyses.
The audiologic evaluation did not involve any 
invasive procedure and all parents and guardians signed 
the informed consent. At the end of the exam, we handed 
the results of this audiologic evaluation to the children’s 
parents or guardians.
RESULTS
There were more males in the sample (52.1%) than 
females. Caucasians were also more common (83.0%), 
followed by browns (11.7%). Age at diagnosis varied 
between 0 and 18 years (mean of 6.8 years; standard de-
viation of 4.9 years; median of 5.6 years), and less than 
half of the patients were diagnosed before 5 years of age 
(45.7%). Current age varied between 1 and 18 years (mean 
age of 8.6 years; standard deviation of 4.8 years; median 
of 7.4 years) and the most frequently found age range 
was between 5 and 9 years (38.3%), followed by that of 
Table 1. Number and percentage of patients, according to topogra-
phy and the use of cisplatin and/or ifosfamide.
Topography # %
Lymphoid leukemia 29 30.8
Bone tumors (osteossarcoma, Ewing’s sarcoma) 8 8.5
Willms’s tumor 8 8.5
Retinoblastoma 7 7.4
Neuroblastoma 6 6.3
Meduloblastoma 5 5.3
Adrenal carcinoma 5 5.3
Nasopharyngeal carcinoma 4 4.3
Hepatoblastoma 4 4.3
Soft tissue sarcomas (rabdomyossarcoma, fuso-
cellular)
4 4.3
Non-lymphoid acute leukemia 4 4.3
Hodgkin’s lymphoma 2 2.1
Malignant histiocytosis 2 2.1
Stem cells tumor 2 2.1
CNS tumor (glioblastoma multiforme) 1 1.1
Non-Hodgkin lymphoma 1 1.1
Thyroid carcinoma 1 1.1
Peripheral neuroectodermal tumor 1 1.1
Total 94 100.0
*(used by one patient who relapsed)
Table 2. Number and percentage of patients according to drug 
used.
Drug # %*
Folinic acid 31 33.0
Dactinomycin 18 19.1
Adriamycin 39 41.5
Arabinosil Citosine (high dose) 15 16.0
Arabinosil Citosine (low dose) 33 35.1
L-Asparaginase (U) 26 27.7
Carboplatin 21 22.3
Cyclophosphamide 46 48.9
Cisplatin 21 22.3
Daunorubicin 27 28.7
Dexametasone 35 37.2
Etoposide 42 44.7
5-Fluorouracil 7 7.4
Ifosfamide 20 21.3
6-Mercaptopurin 32 34.0
Metotrexate (high dose) 34 36.2
Metotrexate (low dose) 35 37.2
Prednisone 5 5.3
Teniposide 11 11.7
Topotecan 6 6.4
Vancomycin 6 6.4
Vinblastine 4 4.3
Vincristine 55 58.5
Metotrexate (MADIT) 29 30.9
AraC (MADIT) 29 30.9
Dexametasone (MADIT) 24 25.5
* Percentage calculated in relation to the 94 patients.
10 years and above (36.2%).
The most frequent diagnosis was of lymphoid leu-
kemia (30.8%), followed by the bone tumors group (8.5%) 
and Willms’s tumor (8.5%) (Table 1). Patients diagnosed 
with lymphoid leukemia, bone tumors, neuroblastoma, me-
duloblastoma, adrenal carcinoma, nasopharyngeal carcino-
ma, hepatoblastoma, soft tissue sarcoma, Hodgkin lympho-
ma, female-germ cells’ tumor, male-germ cells’ tumor and 
peripheral neuroectodermal tumor patients used cisplatin 
and/or ifosfamide. Patients diagnosed with Willms’s tumor, 
retinoblastoma, non-lymphoid acute leukemia, malignant 
histiocytosis, CNS tumor, non-Hodgkin lymphoma and 
thyroid carcinoma did not use these drugs.
Of the 94 patients, 38 (40.4%) had pain in their bo-
dies at the time of diagnosis, followed by fever (34.0%) and 
increase in body mass volume (31.9%). The less frequent 
symptom was motor change (3.2%), mentioned only by 
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three patients.
Among the 94 patients, 67 (71.3%) were alive wi-
thout chemical or radiotherapy treatment at the time of the 
last visit recorded in their medical charts; and 27 (28.7%) 
were alive and under treatment.
Table 2 describes the use of medication with these 
patients. 21 patients (22.3%) used Cisplatin - considered 
highly ototoxic, at a mean individual dose of 78.09 mg/m² 
(standard deviation = 32.69 mg/m²), maximum individual 
dose of 140 mg/m², maximum cumulative dose of 1120 
mg/m² and average number of treatment cycles of 4.24 
(standard deviation = 1.55 cycles).
21 patients (22.3%) received carboplatin, cisplatin-
analogue drug, however of lower ototoxic potential, at a 
mean individual dose of 330.75 mg/m² (standard devia-
tion = 208.21 mg/m²), maximum individual dose of 775 
mg/m², maximum cumulative dose of 4500 mg/m² and 
number of cycles mean value of 4.14 (standard deviation 
= 2.82 cycles).
Most commonly mentioned hearing complaint 
was otitis (22.3%), followed by otalgia (16.0%), dizziness 
(16.0%), hearing difficulties (14.9%) and upper airway 
infections (13.8%).
Table 3 shows the hearing loss classification ac-
cording to the three different classifications. We see that 
according to the ASHA’s classification, 54 (57.5%) patients 
had hearing thresholds within normal limits and 40 (42.5%) 
had some degree of hearing loss. Considering BHL, 82 
(87.2%) patients had hearing thresholds classified in Level 
0 and 12 (12.8%) patients with some degree of hearing 
loss. And finally, considering POGT’s classification, only 56 
(59.6%) patients under levels 0 and 38 (40.4%) had some 
degree of hearing loss, in other words, result very similar 
to the one found by using the ASHA classification.
The agreement in the hearing loss diagnosis accor-
ding to classifications POGT and PAB was weak (Kappa = 
0.36; p <0.001; Table 4), and the same thing happened for 
BHL in relation to ASHA’s (Kappa = 0.33; p<0.001; Table 
5). The agreement between ASHA and POGT was almost 
perfect (Kappa = 0.96; p<0.001; Table 6).
Table 3. Number and percentage of patients according to hearing 
loss classification.
Classification Category Nº %
ASHA
Normal 54 57,5
Mild loss 16 17,0
Light loss 14 14,9
Moderate loss 2 2,1
Moderately severe loss 7 7,4
Severe loss 1 1,1
BHL
Level 0 82 87,2
Level 1 5 5,3
Level 2 2 2,1
Level 3 4 4,3
Level 4 1 1,1
POGT
Level 0 56 59,6
Level 1 29 30,8
Level 2 3 3,2
Level 3 5 5,3
Level 4 1 1,1
TOTAL 94 100,0
Table 4. Number and percentage of patients according to the agree-
ment between classification methods BHL and POGT.
BHL
POGT
Level 0
Levels 1 
through 4
Total
Nº % Nº % Nº %
Level 0 56 100,0 26 68,4 82 87,2
Levels 
1 a 4
-- -- 12 31,6 12 12,8
TOTAL 56 100,0 38 100,0 94 100,0
Kappa = 0,36 (p<0,001)
Table 5. Number and percentage of patients according to the agree-
ment between classification methods BHL and ASHA.
BHL
ASHA
Normal Loss Total
Nº % Nº % Nº %
Level 0 54 100,0 28 70,0 82 87,2
Levels 1 
through 4
-- -- 12 30,0 12 12,8
TOTAL 54 100,0 40 100,0 94 100,0
Kappa = 0,33 (p<0,001)
Table 6. Number and percentage of patients according to the agree-
ment between classification methods POGT and ASHA.
BHL
ASHA
Normal Loss Total
Nº % Nº % Nº %
Level 0 54 100,0 2 5,0 56 59,6
Levels 1 
through 4
-- -- 38 95,0 38 40,4
TOTAL 54 100,0 40 100,0 94 100,0
Kappa = 0,96 (p<0,001)
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DISCUSSION
One of the first things to be highlighted is the hea-
ring evaluation itself is that the institute where this study 
was conducted does not have a department of audiology, 
and is also not specialized in speech and hearing therapy. 
This is not a particularity of this institute, having seen that 
in Brazil pediatric cancer treatment centers still do not have 
a common practice of monitoring patients’ hearing. Thus, 
we recommend that cancer treatment authorities should 
be concerned in installing audiology services in cancer 
treatment centers in order to follow these children and 
teenagers with cancer and also those with other diseases 
that may have their hearing compromised by treatment.
In the hearing loss prevalence analysis by the ASHA 
classification, we found 42.5% of the patients with mild to 
severe hearing loss. In the literature we did not find any 
study that used the ASHA classification. It is important 
to stress that this classification is the strictest among the 
classifications adopted. Patients who had hearing threshold 
above 15 dBHL in any frequency were analyzed as having 
hearing loss. This classification was very much in agree-
ment with the POGT classification (Kappa=0.96), and the 
only difference was that two patients were classified as Le-
vel 0 by POGT, but were considered as having mild loss in 
frequencies below 4000 Hz by the ASHA classification.
The major agreement in the hearing loss diagnosis 
between ASHA’s and POGT’s classification happened 
thanks to the threshold used as cutting point to determi-
ne the hearing loss (15 dBHL for ASHA and 20 dBHL for 
POGT).
When the POGT’s classification was used to classify 
hearing losses, 40.4% of the patients evaluated had hearing 
loss between levels 1 and 4. Among the studies that used 
this classification, the one from Marina et al. (2005)17 with 
24 patients with germ cells tumors, treated with cisplatin, 
found 75% of patients with hearing loss between levels 
2 and 4. In the study developed by Ruiz et al. (1989)18, 
the researchers used the threshold above or equal to 20 
dBHL to classify the hearing loss, and 100% of their patients 
treated with cisplatin had hearing loss.
In the BHL, only those thresholds above or equal to 
40 dBHL are classified as hearing loss. Thus, the number of 
patients with hearing loss using this classification is much 
lower when compared to the other two. The agreement 
between the BHL and the ASHA classifications was weak 
(Kappa=0.33), and the same happened with the POGT 
classification (Kappa=0.36).
When we used the BHL classification, 12.8% of 
the patients evaluated had hearing loss between levels 1 
and 4. Since this classification only considers hearing loss 
above 40 dBHL, the mild or light hearing loss in the ASHA 
classification is classified as Level 0 in the BHL. 
In Skinner et al.’s study (1990)7 involving 22 chil-
dren and adolescents diagnosed with solid tumors and 
treated with cisplatin, 73% had hearing loss. Brock et al. 
(1991)8 found hearing loss in 48% of the 29 children with 
different diagnoses, treated with cisplatin.
Other studies adopted a threshold equal to or above 
25 dBHL in any frequency, between 250 and 8000 Hz as 
a means of hearing loss classification. The percentage of 
loss varied between 43% and 81%2,19-21.
Allen et al. (1998)20 carried out a retrospective study 
with 11 children below 18 years of age who received cis-
platin during chemotherapy between 1985 and 1994. They 
found hearing loss between 25 and 90 dBHL in 81% of the 
children. We found similar figures in the present investi-
gation (83%), when compared to the POGT classification 
(the closest one for the cutting point at 25 dBHL).
Another means to analyze and classify hearing loss 
was by comparing the hearing thresholds of the audiolo-
gic evaluations before and after treatment. Studies which 
adopted an increase in the threshold in any frequency 
equal to or greater than 10 dBHL when compared to the 
previous audiologic evaluation, found between 77% and 
88% of hearing loss in the patients evaluated22,23. In the 
study carried out by Berg et al. (1999)24, hearing loss ha-
ppened to only 26% of the children assessed.
Other studies did not report on which was the 
classification used to classify hearing loss, and hearing 
loss rate varied between 7% and 42%25-27.
Therefore, we see that comparing hearing loss in 
children and teenagers with cancer is very difficult - abo-
ve all - by the use of more or less strict criteria to assess 
hearing.
Smits et al. (2006)28 stressed that hearing loss, even 
when mild, if not detected early on may cause problems 
in the long run. Hearing loss diagnoses in patients being 
treated for cancer is of paramount importance; since it 
may preserve their communications capacity and avoid 
that when they recover from cancer they may have hearing 
sequelae because of their prior treatment29.
We must highlight that using more strict criteria, 
such as the one proposed by the American Speech-Langua-
ge-Hearing Association - ASHA, for hearing loss in children 
is fundamental, because in order to communicate well, the 
child must be able to hear, identify and discriminate all 
speech-related sounds. A reduction in hearing, even if mild, 
compromises the development of such skills, impairing 
understanding and thus, oral communication, it may cause 
emotional, behavioral and educational problems.
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